In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.
FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...
Morning Overview on MSN
Scientists find 'molecular switch' that supercharges natural immunity
A team led by researchers at the University of Cologne has identified a protein called ANKIB1 that acts as a volume dial for the body’s frontline immune defenses, controlling how strongly cells ...
BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma ...
Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...
Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical ...
New regimen for ropeginterferon alfa2b-njft enables patients to reach target dose faster, supporting positive clinical outcomes and enabling faster achievement of maintenance doseBURLINGTON, ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM ESTCompany ParticipantsChristopher Viehbacher - President, CEO ...
Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. A liver function test checks how ...
Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States Division of Infectious Disease and Vaccinology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results